API | fosdagrocorat

fosdagrocorat Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Fosdagrocorat is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM) which was under development for the treatment of rheumatoid arthritis but was never marketed. It is the C2 dihydrogen phosphate ester of dagrocorat, and acts as a prodrug of dagrocorat with improved pharmacokinetics. The drug reached phase II clinical trials prior to the discontinuation of its development. ^Wikipedia

Chemistry

SMILES: Cc1ncccc1NC(=O)c2ccc3c(CC[C@@H]4C[C@@](CC[C@@]34Cc5ccccc5)(OP(=O)(O)O)C(F)(F)F)c2
InChIKey: BVXLAHSJXXSWFF-KEKPKEOLSA-N
Mol. Mass: 574.54
ALogP: 6.28 Partition coefficient
ChEMBL Molecule:
fosdagrocorat

More Chemistry

Pharmacology

Mechanism of Action:
- Glucocorticoid receptor (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

fosdagrocorat | pf-04171327

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (2)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (2)

Arthritis, Rheumatoid (Phase 2)

Healthy Volunteers (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 6
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue